A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Compare the Pharmacokinetics of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production

Cerecin1 个研究点分布在 1 个国家目标入组 16 人开始时间: 2016年11月最近更新: 2017年4月11日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 16
试验地点: 1
主要终点: total ketones AUC0-t

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To compare serum ketone body (i.e., total ketones, β hydroxybutyrate, and estimate of acetoacetate) levels after single dose administration of AC-1204 mixed in water, AC-1202 mixed in water and AC-1202 mixed in Ensure®.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Other
盲法: None

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: Male
接受健康志愿者: 是

入选标准

•Healthy, adult, male 18 55 years of age, inclusive, at screening.
•Continuous non smoker who has not used nicotine containing products for at least 3 months prior to Day -1 of Period 1 and throughout the study.
•Body mass index (BMI) ≥ 20.0 and ≤ 30.0 kg/m2 at screening.
•Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) < the upper limit of normal and triglyceride levels must be < 250 mg/dL.
•A non vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Day -1 of Period
•A subject who has been vasectomized less than 4 months prior to Day -1 of Period 1 must follow the same restrictions as a non vasectomized male).
•Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

排除标准

•Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
•History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
•History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
•History or presence of alcoholism or drug abuse within the past 2 years prior to Day -1 of Period
•History or presence of galactosemia or hypersensitivity or idiosyncratic reaction to the study drugs, related compounds, milk, palm or coconut oil, or soy.
•History or presence of diverticular disease, ulcers, inflammatory bowel disease or recurrent diarrhea or gout.
•Positive urine drug or alcohol results at screening or check in.
•Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
•Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
•Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
•QTcF interval is >460 msec or subject has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.
•Estimated creatinine clearance ≤80 mL/min at screening.
•Unable to refrain from or anticipates the use of any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to Day -1 of Period 1 and throughout the study. Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study.
•Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 28 days prior to Day -1 of Period 1 and throughout the study.
•Is lactose intolerant.
•Is unable to complete the meal prior to Hour 0 on Day -1 of Period 1 and prior to dosing on Day 1 of Period
•Subject consumed grapefruit or Seville oranges within 14 days prior to Day -1 of Period
•Donation of blood or significant blood loss within 56 days prior to Day -1 of Period
•Plasma donation within 7 days prior to Day -1 of Period
•Participation in another clinical study within 28 days prior to Day -1 of Period
•The 28 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day -1 of Period 1 of the current study.